FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 336:367-369 January 30, 1997 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

The success of treatment for childhood acute lymphoblastic leukemia (ALL) has been justifiably lauded. Some 70 percent of patients who receive optimal therapy and support can now expect to have a long-term remission and probable cure.¹ Most current therapeutic protocols use not only early induction and consolidation phases of combination therapy but also a two-year maintenance phase with methotrexate and other drugs. Clinical trials have clearly demonstrated that this protracted treatment is necessary; a shorter duration of maintenance therapy results in more relapses.² After the cessation of chemotherapy, a minority of patients unpredictably relapse within a year or two. Overall, . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Lichtman, M. A. (2008). Battling the Hematological Malignancies: The 200 Years' War. The Oncologist 13: 126-138 [Abstract] [Full Text]  
• Rezuke, W. N., Abernathy, E. C., Tsongalis, G. J. (1997). Molecular diagnosis of B- and T-cell lymphomas: fundamental principles and clinical applications. Clin. Chem. 43: 1814-1823 [Abstract] [Full Text]  
• Dibenedetto, S. P., Schiliro, G., Loscalzo, C. P., Rabkin, C. S., Muller, J., Goedert, J. J., Roberts, W. M., McClain, K. L., Zipf, T. F. (1997). Residual Clones in Childhood Leukemia. NEJM 337: 50-51 [Full Text]